Hikma Pharmaceuticals Plc 15.1% Potential Upside Indicated by Jefferies International

Broker Ratings
[shareaholic app="share_buttons" id_name="post_below_content"]

Hikma Pharmaceuticals Plc using EPIC/TICKER code (LON:HIK) has had its stock rating noted as ‘Reiterates’ with the recommendation being set at ‘BUY’ this morning by analysts at Jefferies International. Hikma Pharmaceuticals Plc are listed in the Health Care sector within UK Main Market. Jefferies International have set their target price at 2240 GBX on its stock. This is indicating the analyst believes there is a potential upside of 15.1% from the opening price of 1946.5 GBX. Over the last 30 and 90 trading days the company share price has decreased 74.5 points and decreased 26.5 points respectively. The 1 year high for the share price is 2212 GBX while the 52 week low for the share price is 1491.5 GBX.

Hikma Pharmaceuticals Plc has a 50 day moving average of 1,952.64 GBX and a 200 day moving average of 1,905.73. There are currently 131,041,980 shares in issue with the average daily volume traded being 373,950. Market capitalisation for LON:HIK is £4,671,913,674 GBP.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:
    Hikma Pharmaceuticals PLC announces agreement to acquire parts of Xellia Pharmaceuticals' US business, expanding its injectables portfolio and manufacturing capabilities.

      Search

      Search